We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Cardiovascular Risk Predicted by Test Measuring HDL Proteins

By LabMedica International staff writers
Posted on 09 Dec 2014
Print article
Image: The composition of High-Density Lipoprotein Cholesterol (Photo courtesy of the University of California Davis).
Image: The composition of High-Density Lipoprotein Cholesterol (Photo courtesy of the University of California Davis).
A new laboratory test has been developed that measures the presence of certain proteins in the High-Density Lipoprotein complex that can lead to an increased risk of cardiovascular disease and mortality.

High-Density Lipoprotein (HDL) is a class of proteins that plays a key role in the body's metabolism of cholesterol and HDL causes the cholesterol to be transported to the liver, where it is broken down and this gives rise to the popular name for HDL of “good cholesterol.” HDL is made up of only around 20% cholesterol and over 50% of HDL is made up of different proteins.

Scientists at the Medical University of Vienna (Austria) measured the concentrations of HDL-associated serum amyloid A (SAA) and surfactant protein B (SP-B) in 1,152 patients with type 2 diabetes mellitus on hemodialysis participating in The German Diabetes Dialysis Study who were randomly assigned to double-blind treatment of 20 mg atorvastatin daily or matching placebo. The association of SAA (HDL) and SP-B (HDL) with cardiovascular outcomes was assessed in multivariate regression models adjusted for known clinical risk factors.

High levels of SAA in the HDL were associated with an increased occurrence of heart attacks, while high levels of SP-B in the HDL acted as a marker for a generally increased risk of mortality. This discovery could change the evaluation of HDL. Clinical practice currently only measures the amount of cholesterol in the HDL (known as the HDL-C) and from which the protective effect against future cardiovascular disease is derived. This relationship may hold true for the healthy population. More recent studies have shown, however, that in many chronic diseases such as coronary heart disease, diabetes mellitus or in patients receiving dialysis, the quantity of HDL-C in the blood cannot be used as a prognostic marker.

The authors concluded that the HDL-C value continues to remain important, however the new test will also in future allow a much more precise risk prediction for cardiovascular diseases, allowing therapy to be commenced much earlier, for example through a modified lifestyle, in order to decisively improve the overall prognosis. In patients with diabetes on hemodialysis, SAA (HDL) and SP-B (HDL) were related to cardiac events and all-cause mortality, respectively, and they were independent of HDL cholesterol. The study was published in the November 2014 issue of the Clinical Journal of the American Society of Nephrology.

Related Links:

Medical University of Vienna


Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
HPV Molecular Controls
ZeptoMetrix® HPV Type 16, 18, 45 & 68 Molecular Controls
New
Aspergillus Test
REALQUALITY Aspergillus

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.